Tight-lipped Cerecor raises $22mn in Series A financing
This article was originally published in Scrip
Keeping details about its lead product close to its chest, the US venture Cerecor announced that it raised $22 million in an overallotment of its Series A preferred stock financing, exceeding the offering's maximum of $15 million but falling short of the $30 million the startup anticipated upon its founding in May 2011.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.